Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double‐Blind, Randomized, Placebo‐Controlled Pilot Trial of Efficacy and Safety

Abstract

Using the current dosing regimen, ibudilast does not improve headache or reduce opioid use in patients with MOH without mandated opioid withdrawal. However, it would be of interest to determine in future trials if ibudilast is able to improve ease of withdrawal during a forced opioid down-titration when incorporated into an MOH detoxification program.